echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > EClinical Media: Toad monoantine therapy increases the risk of death in patients with COVID-19 sepsis.

    EClinical Media: Toad monoantine therapy increases the risk of death in patients with COVID-19 sepsis.

    • Last Update: 2020-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Since March 2020, the COVID-19 outbreak has challenged Spain's health system.
    available therapies (antimalarial drugs, antiviral drugs, biologics) are based on clinical case observation or basic scientific data.
    study aims to characterize the characteristics of patients with COVID-19 severe illness and the effects of different treatment methods on clinical prognosis.
    a retrospective, single-center observational study, the researchers collected sequencing data from adult patients admitted to the University Hospital of Madrid in Quronsalud.
    were included in patients who had tested positive for microbiology (nasal swab RT-PCR) or were epidemiologically diagnosed with severe COVID-19.
    comparing the demographics, underlying diseases, laboratory data, clinical outcomes, and treatment of surviving and non-living patients.
    mortality rates for patients of all ages were 10 March - 15 April 2020, with a total of 607 patients included.
    age of 69 (65 per cent male).
    most common complications were hypertension (46.94%), diabetes (16.16%), chronic heart disease (22.62%) and chronic respiratory disease (19.39%).
    141 patients (23.2%) died.
    In multivariate models, older patients with elevated toad monotherapy, elevated C-reactive proteins upon hospitalization, D-D-djusts and 2.5 ?g/mL, diabetes, or PaO2/FiO2 at hospital were associated with an increased risk of death.
    Only cyclosporine was associated with a significant reduction in mortality in the cumulative in-hospital mortality-specific treatment drugs (toad monoantigen, glucosin, lopinevir/litonave, hydroxychloroquine, cyclosporine) that were not treated with cyclosporine.
    in a real clinical environment, inhibiting the calcium-tuned phosphatase inflammatory path path, NF-T, can reduce the COVID-19 super-inflammatory stage.
    findings may have some guiding significance for the treatment of the disease and may facilitate the design of new clinical trials for patients with COVID-19 severe illnesses.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.